Indole Derivatives for Dengue Prophylaxis via Intermittent Dosing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for dengue disease are limited, with no specific treatment available, and existing vaccines have limitations in widespread use due to factors such as geographic restrictions and unmet medical needs for prophylaxis in humans and animals.
Innovation Solution
The use of substituted indole derivatives and substituted indoline derivatives in the manufacture of medicaments for the prevention and treatment of dengue disease, administered intermittently to inhibit viral replication and reduce the risk of infection, particularly for populations at risk in endemic regions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If no specific treatment is available for dengue disease, then clinical treatment is limited to supportive care, but patient outcomes may deteriorate due to lack of targeted therapy
Solution Approach 1:
The patent applies preliminary action by administering the indole/indoline derivatives as preventive prophylaxis before dengue infection occurs. The compounds are given in advance to travelers or residents in endemic areas to establish protective levels in the body before exposure to the dengue virus, thereby preventing viral replication before it can cause disease progression.
Solution Approach 2:
The patent employs the skipping principle by using intermittent dosing regimens (e.g., once weekly or once monthly) rather than continuous daily administration. This allows the drug to maintain effective concentrations during critical periods while skipping low-risk periods, reducing overall drug exposure and minimizing side effects while still preventing disease progression.
2Adaptability or versatility
If vaccines are restricted to specific geographic settings with high dengue endemicity, then vaccine coverage is limited, but populations in other regions remain unprotected
Solution Approach 1:
The patent applies universality by developing a chemoprophylactic agent that can be used across diverse geographic settings and population groups, not limited to high-endemicity regions. The indole/indoline derivatives provide broad-spectrum protection against all dengue serotypes and can be administered to travelers, residents, and vulnerable populations regardless of their geographic location or prior infection status, making the solution universally applicable.
3Reliability
If compounds are administered frequently to maintain viral levels below detectable limits, then prophylaxis effectiveness is improved, but drug exposure and potential side effects increase
Solution Approach 1:
The patent implements periodic action through intermittent dosing schedules where the indole/indoline derivatives are administered at specific intervals (e.g., once weekly, once every two weeks, or once monthly) rather than continuously. This periodic administration maintains drug levels above the threshold needed to suppress viral replication during high-risk periods while allowing drug levels to decline during lower-risk periods, thereby reducing cumulative drug exposure and potential side effects while preserving prophylaxis effectiveness.
Data Source
AI summary
The present invention relates to the use of substituted indole derivatives and substituted indoline derivatives in the manufacture of a medicament for the treatment of dengue disease in an individual infected by dengue virus or the prevention of dengue disease in an individual at risk of being infected by Dengue virus. The invention further provides a method for the treatment or the prevention of dengue in an individual at risk of being infected by Dengue virus.